ASTRAZENECA has paid $250m for the rights to develop an antibody that could help in the fight against cancer.
The pharmaceutical firm’s research and development arm MedImmune, which is based in Cambridge, has entered into an agreement with Innate Pharma that will allow it exclusive access to the company’s anti-NKG2A antibody.
{iframe}http://www.cambridge-news.co.uk/AstraZeneca-MedImmune-pay-250m-develop-antibody/story-26384707-detail/story.html{/iframe}